K. Rohrmann

Renal cell carcinoma‐infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes

C. Falk, E. Weiss, H. Pohla, 2003, International journal of cancer.

Targeted agents for the treatment of advanced renal cell carcinoma.

N. Haseke, C. Stief, M. Staehler, 2005, Current drug targets.

Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma

P. Nelson, M. Hohenfellner, E. Noessner, 2006, Clinical Cancer Research.

CytotoxicMarkers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma

P. Nelson, M. Hohenfellner, E. Noessner, 2006 .

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

C. Stief, P. Kloepfer, J. Beck, 2011, World Journal of Urology.

Therapeutic approaches in metastatic renal cell carcinoma

C. Stief, D. Zaak, M. Staehler, 2005, BJU international.

Immunotherapy in metastatic renal cell carcinoma

C. Stief, M. Staehler, A. Bachmann, 2005, World Journal of Urology.

Komplette Remission beim pulmonal metastasierten Nierenzellkarzinom durch Inhalationstherapie mit Interleukin-2 nach erfolgloser systemischer Immunchemotherapie

A. Hofstetter, J. Schleypen, K. Rohrmann, 2004, Der Urologe, Ausgabe A.

Symphysitis following transrectal biopsy of the prostate

A. Graser, C. Stief, M. Trottmann, 2006, International journal of urology : official journal of the Japanese Urological Association.